Valeant to acquire Sprout for $1 billion
20 August 2015 | By Victoria White
Valeant has entered into a definitive agreement to acquire Sprout, makers of female libido drug Addyi, for approximately $1 billion...
List view / Grid view
News
Jardiance demonstrates CV risk reduction in type 2 diabetes
20 August 2015 | By Victoria White
Boehringer Ingelheim and Lilly have announced positive top-line results from a clinical study investigating cardiovascular (CV) outcomes for Jardiance...
Vernalis completes investment in NCE development pipeline
20 August 2015 | By Victoria White
Vernalis has announced results from a Phase II proof-of-concept study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor...
Pharma companies rank high on Forbes’ most innovative list
19 August 2015 | By Victoria White
Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine's 2015 list of the "World's Most Innovative Companies"...
NIAID provides more funding to advance ricin vaccine RiVax
19 August 2015 | By Victoria White
NIAID has provided Soligenix an additional $2.7 million in funding to advance the development of its heat stabilised ricin toxin vaccine, RiVax...
Kuros closes successful CHF 15m financing round
19 August 2015 | By Victoria White
Kuros, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, has closed a financing round of CHF15M...
FDA approves female libido drug Addyi
19 August 2015 | By
The US FDA has approved Sprout’s Addyi (flibanserin) to treat acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women...
Bavarian Nordic initiates Phase 1 clinical trial of MVA-BN RSV vaccine
18 August 2015 | By Victoria White
Bavarian Nordic has initiated a Phase 1 clinical study of its MVA-BN vaccine candidate against respiratory syncytial virus (RSV)...
Growth hormone deficiency treatment market value to reach $1.88b by 2024
The global market for growth hormone deficiency (GHD) treatment will rise in value from $1.26 billion in 2014 to reach approximately $1.88 billion by 2024, representing a moderate Compound Annual Growth Rate (CAGR) of 4.08%, according to research and consulting firm GlobalData.
Aspirin reduces obesity-associated cancer risk
18 August 2015 | By Victoria White
An international study of people with a family history of cancer has shown that a regular dose of aspirin reduces the long-term risk of the disease...
B-YOND study results reinforce long-term clinical profile of Alprolix
18 August 2015 | By Victoria White
Interim results from the B-YOND study support the long-term safety and efficacy of Alprolix in people with severe haemophilia B treated for up to two years...
NICE tackles overuse of antibiotics
18 August 2015 | By Victoria White
NICE, the UK health watchdog, has published guidance to help doctors, nurses and pharmacists promote and monitor the sensible use of antibiotics...
EC grants Marketing Authorisation for dinutuximab
17 August 2015 | By Victoria White
The EC has granted Marketing Authorisation for dinutuximab for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years...
Sierra Leone down to last chain of Ebola transmission
17 August 2015 | By Victoria White
An epidemiological week has now passed with no new Ebola cases in Sierra Leone for the first time since the beginning of the outbreak...
Spiolto Respimat provides meaningful quality of life improvements in COPD
17 August 2015 | By Victoria White
New data show Spiolto Respimat provides consistent, clinically meaningful improvements in quality of life versus placebo in patients COPD...
